AbbVie (ABBV)
ABBVPrice: $219.68
Fair Value: 🔒
🔒score
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor f... more
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The compa... more
Description
Shares
| Market Cap | $388.43B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Michael |
| IPO Date | 2013-01-02 | CAGR | 0.1% |
| Employees | 55,000 | Website | www.abbvie.com |
| Div. Yield | 0.89% | Payout Ratio | 2.07% |
| Buy Back Yield | 0.07% | Total Yield | 0.96% |
ABBV chart loading...
Fundamentals
Technicals
| Enterprise Value | $411.21B | P/E Ratio | 92.69 |
| Forward P/E | 13.5 | PEG Ratio | — |
| P/S Ratio | 21.9 | P/B Ratio | -510.1 |
| P/CF Ratio | 97.61 | P/FCF Ratio | 96.86 |
| EPS | $2.37 | EPS Growth 1Y | -1.36% |
| EPS Growth 3Y | -64.37% | EPS Growth 5Y | -17.48% |
| Revenue Growth 1Y | 8.57% | Gross Margin | 0.73% |
| Operating Margin | 0.27% | Profit Margin | 0.07% |
| ROE | 8.8% | ROA | 0.03% |
| ROCE | 0.17% | Current Ratio | 0.72 |
| Quick Ratio | 0.6 | Cash Ratio | 0.14 |
| Debt/Equity | -26.02 | Interest Coverage | 5.77 |
| Altman Z Score | 2.21 | Piotroski Score | 5 |